European stocks are under-performing American stocks at least so far this year. Despite COVID-19 and the ensuing economic chaos, the S&P 500 is down just 12.4% year-to-date. After a dramatic plunge in February and March, equities have rallied sharply. However nobody knows if this rally will hold through the rest of the year.
Compared to the S&P 500, the major European indices have declined more. Germany’s DAX Index is off 18% while the benchmark indices of France, Spain and the UK are all down by over 23% or double of that the S&P 500 year-to-date.
With that brief intro, let’s discuss about growth opportunities in Europe. Unlike the US, Europe is not known for its leadership in the tech sector. There are no European Alphabet (GOOG), Amazon(AMZN), Netflix(NFLX), Apple(AAPL) or Facebook(FB). The reasons for this dismal situation are beyond the scope of this post. However it is possible to find European companies that have decent growth rates.For instance, Europe is home to some world-leading firms in the pharmaceutical and consumer staples sector. The world’s top company for diabetes drugs is based in Denmark. Similarly Switzerland is the home base of consumer good giant Nestle(NSRGY) and pharma majors Roche(RHHBY) and Novartis(NVS).
A recent article in Money Observer discussed a research note from Goldman Sachs that identified the top growth companies in Europe. Similar to moniker FAANG, they assigned the acronym GRANOLAS to this list of high growth European stocks. From the article:
The past decade saw large cap US tech stocks consistently outperform the rest of the market. Anyone with a high weighting towards the likes of Facebook, Apple, Amazon, Netflix and Alphabet (Google) would have outperformed in an already strong bull market. As a result, they earned the collective moniker “Faang stocks,” an acronym for the names of the five companies.
When it comes to European stocks, however, Goldman Sachs, in a new research note, says the so-called GRANOLAS have been the stars. The new acronym stands for GlaxoSmithKline, Roche Holding, ASML, Nestlé,, Novartis, Novo Nordisk, L’Oréal, LVMH, AstraZeneca, SAP and Sanofi.
The past decade has been characterised by low interest rates, slow economic growth and weak earnings growth. Broadly, this has benefited large cap growth tech stocks such as the Faangs.
However, notes Goldman Sachs: “Europe lacks growth companies in general, and in the Technology sector in particular.” Instead, GRANOLAS, all companies with relatively strong balance sheets, low volatility growth and good dividend yields, emerged as Europe’s post-financial crisis winners.
Source: GRANOLAS: The new acronym for Europe’s superstar stocks, Money Observer
Indeed the GRANOLAS are worth considering for investment in these uncertain times. The tickers on the American markets and current dividend yields of this group of stocks are listed below:
1.Company: GlaxoSmithKline (GSK)
Current Dividend Yield: 6.01%
Sector: Pharma
Country: UK
2.Company: Roche Holding AG (RHHBY)
Current Dividend Yield: 2.65%
Sector: Pharmaceuticals
Country: Switzerland
3.Company: ASML Holding NV (ASML)
Current Dividend Yield: 1.04%
Sector: Semiconductor
Country: The Netherlands
4.Company: Nestle SA (NSRGY)
Current Dividend Yield: 2.64%
Sector: Food Products
Country: Switzerland
5.Company: Novartis AG (NVS)
Current Dividend Yield: 3.65%
Sector: Pharmaceuticals
Country: Switzerland
6.Company: Novo Nordisk A/S (NVO)
Current Dividend Yield: 1.94%
Sector: Pharmaceuticals
Country: Denmark
7.Company: L’Oréal S.A. (LRLCY)
Current Dividend Yield: 1.51%
Sector: Personal Care
Country: France
8.Company: LVMH Moet Hennessy Louis Vuitton SA (LVMUY)
Current Dividend Yield: No Dividend Paid
Sector: Luxury Goods
Country: France
9.Company: AstraZeneca PLC (AZN)
Current Dividend Yield: 2.70%
Sector: Pharmaceuticals
Country: UK
10.Company: SAP SE (SAP)
Current Dividend Yield: 1.46%
Sector: Software
Country: Germany
11.Company: Sanofi (SNY)
Current Dividend Yield: 3.74%
Sector: Pharmaceuticals
Country: France
Note: Dividend yields noted above are as of May 1, 2020. Data is known to be accurate from sources used.Please use your own due diligence before making any investment decisions.
Disclosure: No Positions
